Today's top medical abstracts
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Rheumatology
For Practicing
Rheumatologists
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Rheumatologists
Today's Rheumatology News: VGX-1027 To Undergo Additional Testing For RA
D Scott Cunningham MD, PhD, MDLinx Rheumatology
Today's Rheumatology News: FDA Approves Actemra
D Scott Cunningham MD, PhD, MDLinx Rheumatology
From the Editors: New Clinical-Only Option for MDLinx!
Stephen Smith, MDLinx
  See all
fibromyalgia; economic consequences Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Health economic consequences related to the diagnosis of fibromyalgia syndrome
Arthritis & Rheumatism, 03/13/08
Print     Email This Article     Save in My Library   Free Abstract
Annemans L et al. - Failure to diagnose a true case of fibromyalgia syndrome (FMS) is associated with excess general practitioner (GP) visits, investigations, and prescriptions.

Methods
  • Aim was to evaluate the use and costs of medical resources before and after a diagnosis of FMS
  • An existing data set for medical resource use among pts with FMS was applied
  • Costs before diagnosis were used in a trend analysis to predict later costs
  • These predicted costs were compared with the observed costs after diagnosis

Results
  • Following a diagnosis of FMS, a decrease in costs vs. the predicted trend was observed
  • In the 4 yrs after diagnosis, the average difference between the predicted and observed cost was £66.21/6 mos/pt
  • This suggests that making the diagnosis leads to savings and a decrease in resource use
  • The main effect was observed for tests and imaging, followed by pharmaceuticals, referrals, and GP visits

Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.